Ignite Creation Date:
2024-05-06 @ 2:06 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04217954
Status:
COMPLETED
Last Update Posted:
2023-06-23
First Post:
2020-01-01
Brief Title:
HAIC With Oxaliplatin 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
Hepatic Arterial Infusion Chemotherapy With Oxaliplatin 5-fluorouracil and Bevacizumab Plus Intravenous Toripalimab for Advanced Biliary Tract Cancer
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hepatic arterial infusion chemotherapy HAIC deliver high concentration of chemotherapeutic agents directly to the liver tumor was proved to be effective for intrahepatic and perihilar cholangiocarcinoma Based on the potential synergistic effect of bevacizumab chemotherapy and PD-1 inhibitor this phase II clinical study want to test the efficacy and safety using intra-arterial infusion of oxaliplatin 5-fluorouracil and bevacizumab combined with intravenous infusion of PD-1 inhibitor Toripalimab in the treatment of unresectable biliary malignant tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None